Overview
Triamcinolone is a corticosteroid used to treat various inflammatory conditions in the body from allergic rhinitis to acute exacerbations of multiple sclerosis. Triamcinolone can be used as a one time adjunct treatment of osteoarthritic knee pain, or first line as a topical treatment of corticosteroid responsive dermatoses. Triamcinolone is more commonly seen in the forms triamcinolone hexacetonide, triamcinolone acetonide, and triamcinolone diacetate. Triamcinolone was granted FDA approval on 3 December 1957. In October 2021, a suspension of triamcinolone acetonide was approved for suprachoroidal injection - the first suprachoroidal injection to receive FDA approval - for the treatment of patients with macular edema associated with uveitis.
Indication
肾上腺皮质激素类药。主要用于过敏性与自身免疫性炎症性疾病。由于本品潴钠作用较弱，故一般不用作肾上腺皮质功能减退的替代治疗。
Associated Conditions
- Acne
- Acne Vulgaris
- Acute Gouty Arthritis
- Allergic Contact Dermatitis
- Allergic Rhinitis (AR)
- Allergic Skin Reaction
- Alopecia Areata (AA)
- Ankylosing Spondylitis (AS)
- Aphthous Stomatitis
- Asthma
- Atopic Dermatitis
- Autoimmune Hemolytic Anemia
- Berylliosis
- Bullous dermatitis herpetiformis
- Chronic Eczema
- Chronic Inflammatory Skin Diseases
- Congenital Adrenal Hyperplasia (CAH)
- Congenital Hypoplastic Anemia
- Contact Dermatitis
- Crohn's Disease (CD)
- Dental Cavity
- Dermatitis
- Dermatomyositis (DM)
- Diaper Rash
- Discoid Lupus Erythematosus (DLE)
- Edema of the cerebrum
- Epicondylitis
- Erythroderma
- Fungal Infections
- Fungal infectious disorders of the Beard
- Fungal skin infection
- Gingivitis
- Haemorrhoids
- Hemangiomas
- Hypercalcemia
- Inflammation of Mouth
- Intertrigo
- Itching of the Anus
- Itching of the External Genitalia
- Itching of the Foot
- Itching of the genitals
- Itching of the hand
- Juvenile Idiopathic Arthritis (JIA)
- Keloids Scars
- Leukemias
- Lichen Planus (LP)
- Lichen simplex chronicus
- Lymphoma
- Macular Edema
- Mycosis Fungoides (MF)
- Mycotic Eczema
- Necrobiosis lipoidica diabeticorum
- Neurodermatitis
- Nummular Dermatitis
- Ocular Inflammation
- Ophthalmia, Sympathetic
- Oral Erosive Lichen Planus
- Otitis Externa
- Pemphigus
- Pericarditis
- Polymyositis
- Postherpetic Neuralgia
- Primary adrenocortical insufficiency
- Proteinuria
- Psoriasis Vulgaris (Plaque Psoriasis)
- Psoriatic Arthritis
- Psoriatic plaque
- Pure Red Cell Aplasia
- Purulent Wounds
- Pyoderma caused by susceptible bacteria
- Regional Enteritis
- Rheumatoid Arthritis
- Ringworm Folliculitis
- Seborrheic Dermatitis
- Seborrheic Dermatitis, Eczematous
- Secondary Impetiginization
- Secondary adrenocortical insufficiency
- Secondary thrombocytopenia
- Serum Sickness
- Skin chapped
- Stomatitis, Denture
- Synovitis
- Systemic Lupus Erythematosus
- Temporal Arteritis
- Tinea Corporis
- Transfusion Reactions
- Trichinosis
- Tuberculosis (TB)
- Ulcerative Colitis
- Urticaria
- Uveitis
- Wound Infections
- Acute Bursitis
- Acute Multiple sclerosis
- Acute Rheumatic heart disease, unspecified
- Acute Tenosynovitis
- Corticosteroid-responsive dermatoses
- Cutaneous candidiasis
- Cystic tumour of the ganglia
- Exfoliative erythroderma
- Granuloma annulare lesions
- Idiopathic eosinophilic pneumonias
- Non-suppurative Thyroiditis
- Oral infections
- Oral lesions
- Severe Erythema multiforme
- Subacute Dermatitis, Eczematous
- Symptomatic Sarcoidosis
- Ulceration of the mouth
- Ulcerative stomatitis
Research Report
A Comprehensive Monograph on Triamcinolone (DB00620): Pharmacology, Clinical Efficacy, and Safety Profile
Executive Summary
Triamcinolone is a potent, synthetic glucocorticoid of the pregnane steroid class, representing a significant advancement in anti-inflammatory therapy since its initial U.S. Food and Drug Administration (FDA) approval on December 3, 1957.[1] As a derivative of cortisol, it is engineered to maximize anti-inflammatory and immunosuppressive activity while minimizing the mineralocorticoid effects associated with earlier corticosteroids.[3] Its primary clinical value lies in its ability to powerfully modulate the immune system and control inflammation across a wide spectrum of diseases.
The pharmacological activity of Triamcinolone is mediated through its function as a high-affinity agonist for intracellular glucocorticoid receptors.[1] Upon binding, the activated drug-receptor complex translocates to the nucleus, where it modulates gene expression. This genomic mechanism has a dual effect: it upregulates the synthesis of anti-inflammatory proteins, such as lipocortin-1, and simultaneously represses the transcription of pro-inflammatory genes by inhibiting key pathways involving transcription factors like nuclear factor-kappa B (NF-κB). The net result is a profound suppression of the inflammatory cascade, including the inhibition of critical mediators like prostaglandins, leukotrienes, and a host of pro-inflammatory cytokines.[6]
Clinical Trials
View More Clinical Trials
Sign in to access the complete clinical trial database with detailed study information.
Title | Posted | Study ID | Phase | Status | Sponsor |
|---|---|---|---|---|---|
2025/01/29 | Not Applicable | Completed | |||
2025/01/07 | Not Applicable | Not yet recruiting | |||
2024/12/27 | Phase 2 | Recruiting | |||
2024/12/16 | Phase 2 | Not yet recruiting | |||
2024/11/21 | Not Applicable | Recruiting | Brixton Biosciences, Inc. | ||
2024/11/08 | Phase 2 | Not yet recruiting | Francesco Egro | ||
2024/11/08 | Phase 1 | Completed | |||
2024/11/08 | Phase 1 | Recruiting | Inder Paul Singh, M.D. | ||
2024/10/14 | Not Applicable | Recruiting | |||
2024/10/10 | Early Phase 1 | Recruiting |
FDA Drug Approvals
View More FDA Approvals
Sign in to access additional FDA-approved drug information with detailed regulatory data.
Approved Product | Manufacturer | NDC Code | Route | Strength | Effective Date |
|---|---|---|---|---|---|
| Bryant Ranch Prepack | 63629-8779 | TOPICAL | 1 mg in 1 g | 9/1/2021 | |
| Teligent Pharma, Inc. | 52565-048 | TOPICAL | 5 mg in 1 g | 10/7/2021 | |
| A-S Medication Solutions | 50090-0362 | TOPICAL | 0.25 mg in 1 g | 9/28/2021 | |
| Lupin Pharmaceuticals, Inc. | 68180-545 | TOPICAL | 1 mg in 1 g | 1/3/2024 | |
| Proficient Rx LP | 63187-053 | TOPICAL | 1 mg in 1 g | 12/1/2019 | |
| Lupin Pharmaceuticals, Inc. | 68180-952 | TOPICAL | 0.25 mg in 1 g | 12/18/2020 | |
| H.J. Harkins Company, Inc. | 52959-558 | TOPICAL | 1 mg in 1 g | 2/22/2012 | |
| Bryant Ranch Prepack | 63629-9573 | TOPICAL | 1 mg in 1 g | 12/21/2022 | |
| Bryant Ranch Prepack | 63629-8689 | TOPICAL | 1 mg in 1 g | 1/20/2022 | |
| NuCare Pharmaceuticals,Inc. | 68071-2339 | TOPICAL | 1 mg in 1 g | 6/2/2023 |
EMA Drug Approvals
View More EMA Approvals
Sign in to access additional EMA-approved drug information with detailed regulatory data.
Approved Product | Authorization Holder | Status | Issued Date |
|---|---|---|---|
| No EMA approvals found for this drug. | |||
HSA Drug Approvals
View More HSA Approvals
Sign in to access additional HSA-approved drug information with detailed regulatory data.
Approved Product | Manufacturer | Approval Number | Dosage Form | Strength | Approval Date |
|---|---|---|---|---|---|
| TRIAMNONE CREAM 0.1% w/w | SIN07820P | CREAM | 0.1% w/w | 8/2/1994 | |
| ORAL AID LOTION | SIN04696P | LOTION | 0.1% w/v | 6/13/1990 | |
| SHIN POONG TRIAMCINOLONE ACETONIDE INJECTION 40 mg/ml | SIN09801P | INJECTION | 40 mg/ml | 6/4/1998 | |
| ARCATUS® Triamcinolone acetonide suspension for injection 40 mg/mL | SIN17090P | INJECTION, SUSPENSION | 40MG/ML | 9/19/2024 |
NMPA Drug Approvals
View More NMPA Approvals
Sign in to access additional NMPA-approved drug information with detailed regulatory data.
Approved Product | Company | Approval Number | Drug Type | Dosage Form | Approval Date |
|---|---|---|---|---|---|
| No NMPA approvals found for this drug. | |||||
PPB Drug Approvals
View More PPB Approvals
Sign in to access additional PPB-approved drug information with detailed regulatory data.
Approved Product | Registration No. | Company | Licence No. | Strength | Registration Date |
|---|---|---|---|---|---|
| TRODERM CREAM | N/A | N/A | N/A | 11/26/1992 | |
| TRIAMTOL CREAM | N/A | N/A | N/A | 5/20/1988 | |
| ORAL-VICK GEL | N/A | N/A | N/A | 11/19/2007 | |
| PENTACIN CREAM | N/A | N/A | N/A | 6/20/1986 | |
| MXM CREAM | N/A | N/A | N/A | 12/29/2004 | |
| FUOCORTE-F CREAM | N/A | N/A | N/A | 1/30/2003 | |
| PHARMASERVE CREAM | N/A | N/A | N/A | 9/30/2008 | |
| TRIECONA-N CREAM | N/A | N/A | N/A | 6/1/1993 | |
| KENDERM CREAM | N/A | N/A | N/A | 1/7/2005 | |
| ULTRACOMB TOPICAL CREAM | N/A | N/A | N/A | 12/18/1992 |
TGA Drug Approvals
View More TGA Approvals
Sign in to access additional TGA-approved drug information with detailed regulatory data.
Approved Product | ARTG ID | Sponsor | Registration Type | Status | Registration Date |
|---|---|---|---|---|---|
| OTOCOMB Otic ointment tube | 56460 | Medicine | A | 8/7/1996 | |
| ARCATUS triamcinolone acetonide 4 mg/0.1 mL injection suspension vial kit | 410110 | Medicine | A | 1/13/2025 |
Health Canada Drug Approvals
View More Health Canada Approvals
Sign in to access additional Health Canada approved drug information with detailed regulatory data.
Approved Product | Company | DIN | Dosage Form | Strength | Market Date |
|---|---|---|---|---|---|
| THERADERM CREAM | bimeda-mtc animal health inc | 02022818 | Cream - Topical | 1 MG / G | 12/31/1993 |
| NASACORT AQ | sanofi consumer health inc | 02213834 | Spray, Metered Dose - Nasal | 55 MCG / ACT | 12/31/1996 |
| KENACOMB MILD OINTMENT | westwood-squibb, division of bristol-myers squibb canada inc. | 01999834 | Ointment - Topical | .25 MG / G | 12/31/1968 |
| ARISTOCORT SYR 2MG/5ML | lederle cyanamid canada inc. | 00014893 | Syrup - Oral | 2 MG / 5 ML | 12/31/1960 |
| VIADERM KC CRM | 00717002 | Cream - Topical | 1 MG / G | 12/31/1983 | |
| TRIADERM CRM 0.1% | 00716960 | Cream - Topical | 0.1 % | 12/31/1979 | |
| ARISTOCORT R CRM 0.1% | lederle cyanamid canada inc. | 00014621 | Cream - Topical | 1 MG / G | 12/31/1965 |
| ARISTOCORT INJ INTRALESIONAL 25MG/ML | lederle cyanamid canada inc. | 00014834 | Liquid - Intra-Articular
,
Intradermal
,
Intramuscular | 25 MG / ML | 12/31/1962 |
| ARISTOCORT INJ INTRALESIONAL-25MG/ML | glades, division of stiefel canada inc. | 02194147 | Liquid - Intramuscular
,
Intradermal
,
Intra-Articular | 25 MG / ML | 1/20/1997 |
| ARISTOCORT R ONT 0.1% | lederle cyanamid canada inc. | 00127914 | Ointment - Topical | .1 % | 12/31/1969 |
CIMA AEMPS Drug Approvals
View More CIMA AEMPS Approvals
Sign in to access additional CIMA AEMPS approved drug information with detailed regulatory data.
Approved Product | Company | Registration Number | Pharmaceutical Form | Prescription Type | Status |
|---|---|---|---|---|---|
| No CIMA AEMPS (Spain) approvals found for this drug. | |||||
Philippines FDA Drug Approvals
View More Philippines FDA Approvals
Sign in to access additional Philippines FDA approved drug information with detailed regulatory data.
Approved Product | Company | License Number | Dosage Form | Strength | Approval Date |
|---|---|---|---|---|---|
| No Philippines FDA approvals found for this drug. | |||||
Saudi SFDA Drug Approvals
View More Saudi SFDA Approvals
Sign in to access additional Saudi SFDA approved drug information with detailed regulatory data.
Approved Product | Company | License Number | Dosage Form | Strength | Approval Date |
|---|---|---|---|---|---|
| No Saudi SFDA approvals found for this drug. | |||||
Malaysia NPRA Drug Approvals
View More Malaysia NPRA Approvals
Sign in to access additional Malaysia NPRA approved drug information with detailed regulatory data.
Approved Product | Company | Registration Number | Dosage Form | Strength | Approval Date |
|---|---|---|---|---|---|
| No Malaysia NPRA approvals found for this drug. | |||||
UK EMC Drug Information
View More UK EMC Drug Information
Sign in to access additional UK EMC drug information with detailed pharmaceutical data.
Medicine Name | MA Holder | MA Number | Pharmaceutical Form | Active Ingredient | Authorization Date |
|---|---|---|---|---|---|
| No UK EMC drug information found for this drug. | |||||
Help Us Improve
Your feedback helps us provide better drug information and insights.